New platform aims to predict lung cancer treatment success
NCT ID NCT05478538
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study collects extra tissue samples from 200 people with advanced non-small cell lung cancer during routine biopsies. The goal is to train and validate a new diagnostic platform called Cybrid, which aims to predict how well a patient's tumor will respond to immunotherapy. The platform's accuracy will be compared to standard tests like PD-L1 and tumor mutation burden.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a new test that helps doctors predict which lung cancer treatments will work best for each patient.
- What could go wrong
- This is an observational study, not a treatment trial. The platform is still being developed and may not prove accurate enough for clinical use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NSCLC - NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor Scott & White Research Institute
Temple, Texas, 76508, United States
-
Gabrail Cancer Center
Canton, Ohio, 44718, United States
-
JPS Health Network
Fort Worth, Texas, 76104, United States
-
James M Stockman Cancer Institute
Frederick, Maryland, 21702, United States
-
New York Cancer & Blood Specialists
Shirley, New York, 11967, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Cancer drug pralsetinib may change how the body processes other medications
- Blood test may let cancer patients take safe breaks from immunotherapy
- New drug XTX501 takes aim at Hard-to-Treat cancers